Evidence is mounting rapidly with regards to the patient benefit of a prostate cancer care pathway guided by MR imaging and targeted biopsy.  Clinicians at University College London Hospitals have been working over the past five years with researchers in UCL’s Centre for Medical Image Computing to develop an image fusion software for transperineal targeting of the prostate. The resulting CE-marked SmartTarget® device is specifically designed to be agnostic to the clinic’s MR and ultrasound equipment, intuitive for the user, fast to set up and slipping easily into existing clinical workflows with minimal disruption. Having also benefitted from funding by the UK’s Department of Health and the Wellcome Trust, we are pleased to offer a system that is affordable for both the public and private healthcare sectors.

Please contact us today to arrange a demonstration or speak to us further about the benefits and credentials of the SmartTarget® system.